Completed × NIH × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
15 enrolled 9 charts
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Phase 2 Completed
32 enrolled 16 charts
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Phase 2 Completed
116 enrolled 11 charts
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
27 enrolled
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Phase 1/2 Completed
43 enrolled 19 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Phase 1 Completed
71 enrolled
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Phase 2 Completed
116 enrolled 14 charts
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Phase NA Completed
8 enrolled 12 charts
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers
Completed
20 enrolled
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Phase NA Completed
41 enrolled
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Phase 1 Completed
16 enrolled
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Phase 2 Completed
102 enrolled
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Stem Cell Transplantation for Patients With Cancers of the Blood
Phase 2 Completed
61 enrolled 6 charts
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
Phase 1 Completed
110 enrolled
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation
Phase 1 Completed
11 enrolled
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Phase 1 Completed
24 enrolled
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Phase 1/2 Completed
36 enrolled 14 charts
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Phase 2 Completed
15 enrolled 10 charts
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 1/2 Completed
52 enrolled 10 charts
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
Phase 1 Completed
4 enrolled
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Phase 2 Completed
23 enrolled 11 charts
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
Phase 2 Completed
50 enrolled 12 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
Phase 2 Completed
7 enrolled 6 charts
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
Phase 1 Completed
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
Phase NA Completed
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
48 enrolled
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
Phase 1 Completed
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Phase 1 Completed
25 enrolled
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Completed
105 enrolled
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
39 enrolled
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Phase 2 Completed
48 enrolled 5 charts
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
89 enrolled 9 charts
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
102 enrolled 10 charts